VENUS REMEDIES
|
The Current P/E Ratio of VENUS REMEDIES is 20.53.
| Share Price | ₹1,780.1 | Aug 17,2026 |
| Market Cap | ₹2,385.3 Cr | |
| Earnings-TTM | ₹116.2 Cr | TTM-Consolidated Results |
| Price/Earnings | 20.53x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of VENUS REMEDIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹2,385.3 Cr] as on Aug 17,2026
(/) Earnings [ ₹116.2 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 20.53x ]
Thus, for VENUS REMEDIES , the investors are currently willing to pay 20.53 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of VENUS REMEDIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of VENUS REMEDIES over the last five years.
Historical PE (Price/Earnings) ratio chart of VENUS REMEDIES
PE Ratio Performance Analysis for VENUS REMEDIES
- VENUS REMEDIES 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 10.37x.
- VENUS REMEDIES 's operated at median p/e ratio of 8.84x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, VENUS REMEDIES 's p/e ratio peaked in Mar2024 at 15.31x.
- VENUS REMEDIES 's p/e ratio hit its five-year low in Mar2023 of 8.15x.
How does VENUS REMEDIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| VENUS REMEDIES | 116.17 | 20.53 | 2,385.3 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 37.11 | 451,675.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 77.10 | 225,516.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 86.36 | 186,190.0 |
| CIPLA LTD | 3,364.84 | 34.33 | 115,523.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 31.39 | 99,493.4 |
| MANKIND PHARMA LTD | 2,055.11 | 48.23 | 99,117.0 |
| LUPIN LTD | 5,551.01 | 18.61 | 103,299.0 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 25.14 | 112,917.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 25.18 | 93,498.9 |
| LAURUS LABS LTD | 1,090.76 | 89.11 | 97,202.2 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs VENUS REMEDIES 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.61x |
| Max industry PE | 89.11x |
| Median industry PE | 34.33x |
| Average industry PE | 44.83x |
You may also like the below Video Courses